A MiR-SNP Of XPO5Gene Is Associated With Clinical Characteristics And Survival Of Small Cell Lung Cancer

Objective：Worldwide，lung cancer is one of the most common malignanttumors, it showed an increasing trend in morbidity and mortality, it is theleading cause of the global variety of cancer-related death. MicroRNA isabundant class of small non-protein-coding RNA.The length of matureMicroRNA is22nt, it is generated by approximately70nt hairpin structureMicroRNA precursor after enzyme Dicer processing. Single nucleotidepolymorphisms (SNPs) is caused by a single nucleotide variations of DNAsequence polymorphism at the genomic level. XPO5exist in the nuclearmembrane，it mediated transport of pre-miRNA，so as to regulate miRNAexpression. microRNA-related single nucleotide polymorphisms (miR-SNPs)in miRNA processing machinery genes can affect cancer risk, treatmentefficacy and patients prognosis. This study analyzes the relationship betweenMiR-SNP of XPO5gene and the clinical characteristics and survival of smallcell lung cancer patients firstly, at the same time,provide a new direction forthe evaluation of small cell lung cancer patients survive.Methods: The39cases of small cell lung cancer patients were collectedthat were treated in the respiratory department of The Fourth Hospital ofHebei Medical University by histopathology and/or cell pathologicaldiagnosis during2005-2009, and the exclusion of the history of geneticdisease and other malignancy. The general information and survival data ofsmall cell lung cancer patients were accurately recorded. Sacrificing bloodsamples and then using proteinase K-sodium chloride salting-out method toextract DNA, target gene fragment was amplified by polymerase chainreaction, then using LDR technology to detect SNP sites，the XPO5singlenucleotide polymorphisms (SNPs) rs11077were genotyped. Analyze genotypeand survival of39patients with small cell lung cancer patients. All statistics are used SPSS13.0version of statistical software for analysis.Results：1.In all subjects, male25cases, accounting for64.10%; female14cases,accounting for35.90%. The distribution of the age range of32years old to77years old, less60years old accounted for64.10%(n=25),;>60years of agewere accounted for35.90%(n=14). The limited18cases, accounting for46.15%；extensive21cases, accounting for53.85%. Smoking group,21cases,accounting for53.85%；non-smoking group,18cases, accounting for46.15%.Chemotherapy group,31cases, accounting for79.49%;8cases ofchemotherapy plus radiotherapy group, accounting for20.51%.2.Different clinical characteristics of genotype frequency distribution:Male patient group and female patients with AA genotype,CC+AC genotypefrequencies were84%,16%and71.43%,28.57%;≤60years and>60-year-oldAA genotype, CC+AC genotype frequencies were88%,12%and64.29%,35.71%; smoking group and non-smoking group with AA genotype, CC+ACgenotype frequencies were85.71%,14.29%and72.22%,27.78%.3.Univariate analysis: XPO5genotype(AA genotype and AC+CCgenotype,p=0.005) influence on survival were statistically significant. Gender(male and female, P=0.15), age (≤60years of age and>60years, P=0.12),staging (for limited and extensive stage, P=0.375), smoking status (smokingand non-smoking, P=0.727), treatment (chemotherapy and chemotherapy plusradiotherapy group, P=0.730) influence on survival were statisticallysignificant. Multivariate analysis: Genotype XPO5genotype (P=0.007, RR=3.262,95%CI=1.387~7.671) associated with the risk of death of patientswith SCLC. Gender was not related with risk of death in SCLC patients（P=0.079，RR=0.518，95%CI=0.249~1.080）.Age was not related with riskof death in SCLC patients（P=0.286，RR=1.458，95%CI=0.730~2.911）.Conclusions:1.XPO5gene rs11077polymorphic sites AA genotype patients had a longersurvival (P=0.005).2.By multivariate analysis, The XPO5gene rs11077polymorphic sites genotype as an independent risk factor for the survival of patients with smallcell lung cancer (P=0.007, relative risk3.262,95%CI=1.387to7.671),compared with AC+CC genotype SCLC patients,the AA genotype of SCLCpatients survival was long.3.Gender, age, stage, smoking status, treatment is not yet an independent riskfactor for survival of patients with SCLC.